Search Results

Oryzon Genomics, S.A. announced the voting results from its Annual General Meeting of Shareholders held in Madrid.

Oryzon Genomics, S.A announced today that its management will give an update on corporate progress at several international events in June.

Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in April.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in May.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination with azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML) were published online in The Lancet Hematology.

Oryzon Genomics, S.A. announced a public approval from the EU Commission, under EU State aid rules, of the first Important Project of Common European Interest to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update on recent developments.

Oryzon Genomics, S.A. today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an oral presentation at the 37th European College of Neuropsychopharmacology (ECNP) annual conference, to be held on September 21-23, 2024 in Milan, Italy.